<SEC-DOCUMENT>0001000694-24-000040.txt : 20241112
<SEC-HEADER>0001000694-24-000040.hdr.sgml : 20241112
<ACCEPTANCE-DATETIME>20241112080448
ACCESSION NUMBER:		0001000694-24-000040
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20241112
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241112
DATE AS OF CHANGE:		20241112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVAVAX INC
		CENTRAL INDEX KEY:			0001000694
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				222816046
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26770
		FILM NUMBER:		241443537

	BUSINESS ADDRESS:	
		STREET 1:		700 QUINCE ORCHARD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
		BUSINESS PHONE:		240-268-2000

	MAIL ADDRESS:	
		STREET 1:		700 QUINCE ORCHARD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nvax-20241112.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:84ddd817-58e9-4ee2-8fb2-442252d0bcaf,g:202b5dd4-bf57-4ed9-9f0e-a8458559e034,d:5912a221f39149fa89526a2567425a81-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nvax-20241112</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-21">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001000694</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nvax-20241112.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-12</xbrli:startDate><xbrli:endDate>2024-11-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5912a221f39149fa89526a2567425a81_1"></div><div style="min-height:18pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Washington, D.C. 20549 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:700;line-height:100%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OF THE SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 12, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">NOVAVAX, INC</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in charter) </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.418%"><tr><td style="width:1.0%"/><td style="width:30.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">0-26770</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">22-2816046</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or Other Jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">700 Quince Orchard Road</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Gaithersburg</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Maryland</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">20878</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices, including Zip Code) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">(240)</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">268-2000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Former name or former address, if changed since last report.) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.700%"><tr><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.700%"><tr><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.700%"><tr><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.700%"><tr><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.418%"><tr><td style="width:1.0%"/><td style="width:40.433%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading <br/>Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which <br/>registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, Par Value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">NVAX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="padding-left:216pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:216pt;text-indent:-216pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5912a221f39149fa89526a2567425a81_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.02. Results of Operations and Financial Condition.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Second Quarter Financial Results</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On November 12, 2024, Novavax, Inc. (the &#8220;Company&#8221;) issued a press release announcing the Company&#8217;s financial results for the quarter ended September 30, 2024. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5912a221f39149fa89526a2567425a81_10"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9.01. Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.276%"><tr><td style="width:1.0%"/><td style="width:9.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a3q24earningspressrelease2.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a3q24earningspressrelease2.htm">Press release, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a3q24earningspressrelease2.htm">November</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a3q24earningspressrelease2.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a3q24earningspressrelease2.htm">12</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a3q24earningspressrelease2.htm">, 2024, regarding the Company&#8217;s financial results for the quarter ended  </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a3q24earningspressrelease2.htm">September 30</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a3q24earningspressrelease2.htm">, 2024.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL).</span></td></tr></table></div><div id="i5912a221f39149fa89526a2567425a81_13"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.418%"><tr><td style="width:1.0%"/><td style="width:47.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.831%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOVAVAX, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 12, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark J. Casey</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark J. Casey</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Legal Officer and Corporate Secretary</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a3q24earningspressrelease2.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7e200f4bb95843b4961f701e1295ce47_1"></div><div style="min-height:99pt;width:100%"><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #1f497d;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#1f497d;font-family:'Arial',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Press Release</font></td><td colspan="3" style="border-bottom:1pt solid #1f497d;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #1f497d;padding:0 1pt"><div style="margin-bottom:8pt;text-align:right"><img alt="image_03a.jpg" src="image_03a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"></div></td></tr></table></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Achieved total revenue of $85 million in the third quarter of 2024 </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Ended the third quarter of 2024 with $1 billion in cash and receivables</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Received authorization from U.S. FDA and European Commission for updated 2024-2025 formula COVID-19 vaccine in individuals aged 12 and older</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Outlined R&#38;D strategy based on its proven technology platform</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Updates full year 2024 financial guidance</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Company to host conference call today at 8&#58;30 a.m. ET</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GAITHERSBURG, Md., Nov. 12, 2024 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211; Novavax, Inc. (Nasdaq&#58; NVAX), a global company advancing protein-based vaccines with its Matrix-M&#8482; adjuvant, today announced its financial results and operational highlights for the third quarter ended September 30, 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Novavax continues to focus on our corporate growth strategy of driving value from additional business development activities and organic R&#38;D using our proven technology platform,&#8221; said John C. Jacobs, President and Chief Executive Officer, Novavax. &#8220;In addition to progress on our other value drivers, this past quarter, we made significant progress defining our R&#38;D strategy as we look to expand beyond COVID-19 and influenza. We intend to develop our early-stage pipeline with a disciplined approach, as we focus on areas where our technology can have a positive impact on public health and generate value.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Quarter 2024 and Recent Highlights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">During the third quarter, Novavax continued executing against its four key priorities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Priority #1&#58; Successful Execution of Sanofi Partnership</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Advanced preparation for Sanofi to assume lead commercial responsibility of Nuvaxovid&#8482; COVID-19 vaccine for 2025-2026 vaccination season in the U.S., Europe and select major markets not currently subject to Novavax Advanced Purchase Agreements (APAs) or existing partnership agreements.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">On track for the Novavax pediatric clinical trial database lock for the first cohort in the fourth quarter of 2024, achievement triggers a $50 million milestone payment. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Priority #2&#58; Drive Incremental Value from Novavax&#8217;s Proven Technology Platform</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">In November 2024, the U.S. Food and Drug Administration (FDA) removed the clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. Novavax is working to initiate the Phase 3 immunogenicity clinical trial for CIC and stand-alone influenza candidates as soon as possible. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Signed a Matrix-M adjuvant related agreement with a leading pharmaceutical company to enable exploration of our technology for the potential advancement of their pipeline candidates.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Outlined guiding principles of new Research &#38; Development (R&#38;D) strategy based on its proven technology platform and announced the appointment of Ruxandra Draghia-Akli, MD, PhD as Executive Vice President and Head of R&#38;D. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Continued to advance pandemic influenza and respiratory syncytial virus (RSV) pre-clinical programs towards IND readiness, with a focus on RSV-combination options.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Priority #3&#58; Continue Evolution of Novavax and Reduce Operating Expenses</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">On track with cost structure improvements, including an approximate 26% reduction in combined R&#38;D and </font><font style="color:#212121;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Selling, General and Administrative</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (SG&#38;A) expenses in the third quarter of 2024 compared to the same period for 2023. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.1pt">Targeting full year combined R&#38;D and SG&#38;A expenses of approximately $500 million for full year 2025 and approximately $350 million for full year 2026.  A portion of these expenses are expected to be reimbursed under the Sanofi Agreement. The full year 2026 target spend reflects a reduction of approximately $1.4 billion and 80% as compared to full year 2022.  </font></div><div style="margin-bottom:8pt;padding-left:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Priority #4&#58; Deliver an Updated COVID-19 Vaccine for the 2024-2025 Vaccination Season</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">U.S. Market&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Received Emergency Use Authorization (EUA) from the U.S.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FDA in individuals aged 12 and older.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Entered the market with an improved product presentation and broader access -Nuvaxovid&#8482; available in pre-filled syringe presentation in over 30,000 locations across major pharmacy retailers and regional grocers in the U.S.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Novavax's COVID-19 vaccine Biologics License Application (BLA) Prescription Drug User Fee Act with an action date of April 2025 and updated to include both JN.1 variant and pre-filled syringe presentation. Achievement of BLA approval triggers a $175 million milestone payment from Sanofi.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Global Markets&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Received global authorizations including in the European Union, Canada, and Taiwan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Quarter 2024 Financial Results </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Total revenue </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">for the third quarter of 2024 was $85 million, compared to $187 million in the same period in 2023.  Product sales of $38 million for the third quarter 2024 related to primarily U.S. market commercial sales. Licensing, royalties and other revenue of $46 million in the third quarter of 2024 related to a combination of activities under the Sanofi Agreement and adjuvant sales. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Cost of sales</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for the third quarter of 2024 was $61 million, compared to $99 million in the same period in 2023. These quarters included $28 million and $74 million, respectively, related to excess, obsolete or expired inventory, losses on firm purchase commitments under third-party supply agreements and unutilized manufacturing capacity.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">R&#38;D expenses </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">for the third quarter of 2024 were $87 million, compared to $106 million in the same period in 2023. The decrease was primarily due to reductions in manufacturing and clinical research-related spend.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">SG&#38;A expenses </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">for the third quarter of 2024 were $71 million, compared to $107 million for the same period in 2023. The decrease was primarily due to cost reduction activities, partially offset by commercialization expenses for Nuvaxovid.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Net loss </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">for the third quarter 2024 was $121 million, compared to a net loss of $131 million in the same period in 2023.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Cash, cash equivalents, marketable securities and restricted cash</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Cash)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> were $924 million as of September 30, 2024, compared to $584 million as of December 31, 2023.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial Framework</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Novavax is updating its Full Year 2024 Financial Guidance and expects to achieve the following objectives. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Full Year 2024 Guidance</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.128%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8239;</font></div><div style="padding-right:-2.63pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$ in millions</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prior</font></div><div style="padding-right:-2.63pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(as of Aug. 8, 2024)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Updated</font></div><div style="padding-right:-2.63pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(as of Nov. 12, 2024)</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total Revenue</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$700 - $800</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$650 - $700</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> 1</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$275 - $375</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$175 - $225</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing, Royalties and Other Revenue</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> 2</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$425</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$475</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Combined R&#38;D and SG&#38;A</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$700 - $750</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$700 - $750</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.67pt">Full year 2024 product sales guidance reflects approximately $100 million in APA dose deliveries in 1H 2024 and $75 million to $125 million of commercial market sales in 2H 2024. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.67pt">Full year 2024 Licensing, royalties and other revenue guidance includes $450 million of revenue recognition from the $500 million Sanofi agreement upfront payment and $25 million in royalty and other revenue from partner-related activities.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Conference Call</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Novavax will host its quarterly conference call today at 8&#58;30 a.m. ET. To join the call without operator assistance, you may register and enter your phone number at</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;emportal.ink&#47;3Y6irHG </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to receive an instant automated call back. You may also dial direct to be entered to the call by an operator. The dial-in numbers for the conference call are (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International). Participants will be prompted to request to join the Novavax, Inc. call. A replay of the conference call will be available starting at 11&#58;30 a.m. ET on November 12, 2024, until 11&#58;59 p.m. ET on November 19, 2024. To access the replay by telephone, dial (888) 660-6345 (Domestic) or (+1) (646) 517-4150 (International) and use passcode 62491 #.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A webcast of the conference call can also be accessed on the Novavax website at </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ir.novavax.com&#47;events</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A replay of the webcast will be available on the Novavax website until December 12, 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Trade Name in the U.S.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The trade name Nuvaxovid has not been approved by the U.S. FDA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Novavax</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Novavax, Inc. (Nasdaq&#58; NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes </font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CIC and stand-alone influenza vaccine candidates</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21&#47;Matrix-M malaria vaccine. Please visit </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">novavax.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">LinkedIn</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for more information.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company has used a non-GAAP financial measure in this press release, which is adjusted combined R&#38;D and SG&#38;A expenses, net of Sanofi reimbursement costs under the Sanofi Agreement. Non-GAAP financial measures refer to financial information adjusted from financial measures prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company believes that the presentation of this adjusted financial measure is useful to investors as it provides additional information on comparisons between periods by including certain items that affect overall comparability. The Company uses this non-GAAP financial measure for business planning purposes and to consider underlying trends of its business and believes presenting this measure also provides useful information to investors and others for understanding and evaluating trends in the Company&#8217;s expenses in the same manner as the Company&#8217;s management. Non-GAAP financial measures should be considered in addition to, and not as an alternative for, the Company&#8217;s reported results prepared in accordance with GAAP. The use of this non-GAAP financial measure may differ from similar measures reported by other companies and may not be comparable to other similarly titled measures. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Forward-Looking Statements </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Statements herein relating to the future of Novavax, its mission&#59; its corporate strategy and operating plans, objectives and prospects&#59; its value drivers and near-term priorities, its partnerships, including expectations with respect to potential royalties, milestones, and cost reimbursement, and plans for additional potential partnering activities&#59; its expectations regarding manufacturing capacity, timing, production and delivery for its COVID-19 vaccine&#59; the development of Novavax&#8217;s clinical and preclinical product candidates and innovation expansion opportunities&#59; the conduct, timing and potential results from clinical trials and other preclinical studies&#59; scope, timing and outcome of future and pending regulatory filings and actions, including the potential BLA approval for Novavax&#8217;s COVID-19 vaccine&#59; potential market sizes and demand for its COVID-19 vaccine and product candidates&#59; full year 2024 financial guidance&#59; and the amount and impact of Novavax&#8217;s cost reduction plans&#59; and Novavax&#8217;s future financial or business performance.  Novavax cautions that these forward-looking statements are subject to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, Novavax&#8217;s ability to successfully and timely manufacture, market, distribute, or deliver its updated 2024-2025 formula COVID-19 vaccine and the impact of its not having received a BLA from the FDA for the 2024-2025 vaccination season&#59; challenges related to Novavax&#8217;s partnership with Sanofi and in pursuing additional partnership opportunities&#59; challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification, assay validation and stability testing, necessary to satisfy applicable regulatory authorities&#59; challenges or delays in conducting clinical trials or studies for its product candidates&#59; challenges or delays in obtaining regulatory authorization for its product candidates, including for future COVID-19 variant strain changes, its CIC vaccine candidate, its stand-alone influenza vaccine candidate or other product candidates&#59; manufacturing, distribution or export delays or challenges&#59; Novavax&#8217;s substantial dependence on Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for co-formulation and filling Novavax&#8217;s COVID-19 vaccine and the impact of any delays or disruptions in their operations&#59; difficulty obtaining scarce raw materials and supplies including for its proprietary adjuvant&#59; resource constraints, including human capital and manufacturing capacity&#59; constraints on Novavax&#8217;s ability to pursue planned regulatory pathways, alone or with partners&#59; challenges in implementing its global restructuring and cost reduction plan&#59; challenges in obtaining commercial adoption and market acceptance of its updated 2024-2025 formula COVID-19 vaccine or any COVID-19 variant strain containing formulation, or for its CIC vaccine candidate and stand-alone influenza vaccine candidate or other product candidates&#59; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities, including requirements to deliver doses that may require Novavax to refund portions of upfront and other payments previously received or result in reduced future payments pursuant to such agreements and challenges in amending or terminating such agreements&#59; challenges related to the seasonality of vaccinations against COVID-19&#59; challenges related to the demand for vaccinations against COVID-19 or influenza&#59; challenges in identifying and successfully pursuing innovation expansion opportunities&#59; Novavax&#8217;s expectations as to expenses and cash needs may prove not to be correct for reasons such as changes in plans or actual events being different than its assumptions&#59; and those other risk factors identified in the &#8220;Risk Factors&#8221; and &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.novavax.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">NOVAVAX, INC.</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-1.13pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="padding-right:-1.13pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(in thousands, except per share information)</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.760%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Three Months Ended</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Nine Months Ended</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2024</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2024</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#212121;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#212121;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(unaudited)</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Revenue&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;Product sales</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$        38,210  </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$         2,231  </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$     140,438</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$    279,937</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;Licensing, royalties and other</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">46,302</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">19,833</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">453,413</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">23,046</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;Grants</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">--</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">164,922</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">--</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">389,380</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 35.87pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total revenue</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">84,512</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">186,986</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">593,851</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">692,363</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Expenses&#58;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;Cost of sales</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;&#160;60,619</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;98,929</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">166,070</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">188,792</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;Research and development</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">87,164</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;106,229</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">286,789</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">572,805</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;Selling, general and administrative</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">70,747</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">107,460</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">258,843</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">313,709</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 35.87pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total expenses</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">218,530</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">312,618</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">711,702</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,075,306</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;Loss from operations</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(134,018)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(125,632)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(117,851)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(382,943)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest expense</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(4,236)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2,859)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(12,490)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(10,299)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other income (expense), net</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">15,922</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2,982)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">27,307</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">26,912</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Loss before income tax expense (benefit)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(122,332)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(131,473)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(103,034)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(366,330)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-1.13pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Income tax expense (benefit)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(1,032)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(697)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">3,435</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">343</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net Loss</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$     (121,300)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$   (130,776)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$     (106,469)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$  (366,673)</font></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss per share&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;Basic and diluted </font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$             (0.76)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$        (1.26)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$           (0.71)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$        (3.94)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Weighted average number of common shares outstanding&#58;</font></td><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;Basic and diluted</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">160,049</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">103,429</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">149,486</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">93,046</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:8pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SELECTED CONSOLIDATED BALANCE SHEET DATA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(in thousands)</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.266%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:1.87pt;text-align:justify"><font><br></font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.87pt;padding-right:1.87pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</font></div><div style="padding-left:1.87pt;padding-right:1.87pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.87pt;padding-right:1.87pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</font></div><div style="padding-left:1.87pt;padding-right:1.87pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:1.87pt;text-align:justify"><font><br></font></div></td><td colspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:1.87pt;text-align:justify"><font><br></font></div></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:1.87pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.72pt;padding-right:1.87pt;text-align:right;text-indent:0.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;      </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">573,630</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.87pt;padding-right:-2.63pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$          </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">568,505       </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:1.87pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</font></div></td><td colspan="6" style="padding:2px 2.87pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">335,901</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.87pt;padding-right:-2.63pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">--</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:1.87pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total restricted cash</font></div></td><td colspan="6" style="padding:2px 2.87pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">14,957</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.87pt;padding-right:-2.63pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15,305</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:1.87pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</font></div></td><td colspan="6" style="padding:2px 2.87pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,103,680</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,143,888</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:1.87pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working capital</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></td><td colspan="6" style="padding:2px 2.87pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;(77,319)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;(491,250)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:1.87pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</font></div></td><td colspan="6" style="padding:2px 2.87pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,712,483</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,797,490</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:1.87pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible notes payable</font></div></td><td colspan="6" style="padding:2px 2.87pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;169,265</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;168,016</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:1.87pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; deficit</font></div></td><td colspan="6" style="padding:2px 2.87pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(526,436)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;(716,927)</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contacts&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investors</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Luis Sanay, CFA</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">240-268-2022</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ir&#64;novavax.com</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Media</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Giovanna Chandler</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">202-709-5563</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">media&#64;novavax.com</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div></div></div><div id="i7e200f4bb95843b4961f701e1295ce47_35"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>nvax-20241112.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:84ddd817-58e9-4ee2-8fb2-442252d0bcaf,g:202b5dd4-bf57-4ed9-9f0e-a8458559e034-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nvax="http://www.novavax.com/20241112" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.novavax.com/20241112">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20241112_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20241112_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.novavax.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>nvax-20241112_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:84ddd817-58e9-4ee2-8fb2-442252d0bcaf,g:202b5dd4-bf57-4ed9-9f0e-a8458559e034-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_b693d029-72d6-4140-b2a6-d0ef37eff3be_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3cbd8e38-122d-4aff-a52d-136e4e71e4e1_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_7968705d-c621-4632-ae02-db16a96774d2_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bc036aef-d8e3-434b-9024-1a0d4917a0cb_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5a017654-d307-45af-82fa-d515a64a6cd7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5f65de6d-5d7b-4316-b315-74f46d6c57f2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7e13c998-5c1b-4151-bf49-d9acff63241a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_418ceae9-dff8-4df7-a61d-fcf5388a917a_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_94dbeab9-7b59-4665-95ec-e64014b757f0_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ef44787f-6b60-42c2-93eb-0fac456542c9_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_bd1ea7b5-165e-42bb-9627-5effe1be470c_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_88902c8c-d353-4e66-98c5-b93eae38a53e_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6187bf33-4e9b-4cef-a1f8-eaea649b282a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a91965cc-5586-4b01-ae91-bc7fe075f30c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ce2edda4-8ae4-40d5-974f-da86bff74059_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3615b4d1-b07f-4333-8fae-9216ac117687_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_afe2c765-3dfd-4190-8cdb-fba2c5aa4075_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_60312723-eb84-40c6-9881-3ad737edbedc_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c760ab24-c8ec-4c21-8304-1a1639539c38_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_4105cbf7-64f1-4219-bf8e-7bbe818d1c10_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_291eee5c-d41e-4fb3-8fea-fb08a25b0d40_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d33f3a0e-672d-4aab-899d-4818b2e2606e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>nvax-20241112_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:84ddd817-58e9-4ee2-8fb2-442252d0bcaf,g:202b5dd4-bf57-4ed9-9f0e-a8458559e034-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.novavax.com/role/CoverPage" xlink:type="simple" xlink:href="nvax-20241112.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_dc39de9a-813e-4132-a003-a678441d7c98" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_DocumentType_dc39de9a-813e-4132-a003-a678441d7c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_2bbd305e-5f39-4288-859d-dbf4472a01c1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_DocumentPeriodEndDate_2bbd305e-5f39-4288-859d-dbf4472a01c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a18d11cd-5b4a-494e-a648-23518b15ec8c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_EntityRegistrantName_a18d11cd-5b4a-494e-a648-23518b15ec8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_72f5b6fe-ef8c-473d-8618-96d91e2354b9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_EntityIncorporationStateCountryCode_72f5b6fe-ef8c-473d-8618-96d91e2354b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_16473ecf-ec80-43a4-8f24-c3be625ec193" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_EntityFileNumber_16473ecf-ec80-43a4-8f24-c3be625ec193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_747e2d1f-05f1-4ee8-a9ce-3316d30fe859" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_EntityTaxIdentificationNumber_747e2d1f-05f1-4ee8-a9ce-3316d30fe859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0a1b4e6f-eb67-4243-8e04-25521062268e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_EntityAddressAddressLine1_0a1b4e6f-eb67-4243-8e04-25521062268e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c43a5858-bece-4ebb-8a0f-e4e58bdfe5c1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_EntityAddressCityOrTown_c43a5858-bece-4ebb-8a0f-e4e58bdfe5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c3b0102c-efb7-47f0-81d4-057f3bcd66bf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_EntityAddressStateOrProvince_c3b0102c-efb7-47f0-81d4-057f3bcd66bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4e78e0fd-0678-48c7-8084-76ac86cd659b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_EntityAddressPostalZipCode_4e78e0fd-0678-48c7-8084-76ac86cd659b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9186a8ac-6bc4-4fc0-9568-7f0d568b938c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_CityAreaCode_9186a8ac-6bc4-4fc0-9568-7f0d568b938c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_59802ce5-bd5d-48a7-b675-082053f139f5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_LocalPhoneNumber_59802ce5-bd5d-48a7-b675-082053f139f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_4278deb4-e9ab-4626-817a-3b54db10b0fd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_WrittenCommunications_4278deb4-e9ab-4626-817a-3b54db10b0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_1714a86c-6a18-4aa7-9140-b65715402164" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_SolicitingMaterial_1714a86c-6a18-4aa7-9140-b65715402164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_f11c164a-1647-4a7e-acf9-2d94f40fb5ef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_PreCommencementTenderOffer_f11c164a-1647-4a7e-acf9-2d94f40fb5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_44f4b12c-a433-44cf-9b5c-2d0a82e4e664" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_44f4b12c-a433-44cf-9b5c-2d0a82e4e664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b1503976-6e9f-444c-96d6-cd2cac0e62cf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_Security12bTitle_b1503976-6e9f-444c-96d6-cd2cac0e62cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_48a81ade-14fe-42f4-9f17-a7fadc1ff30f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_TradingSymbol_48a81ade-14fe-42f4-9f17-a7fadc1ff30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6d39f01b-cb59-45ef-8ab3-6a9cd951160b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_SecurityExchangeName_6d39f01b-cb59-45ef-8ab3-6a9cd951160b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7d4078fb-cfef-46bb-a477-76904a3853be" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_EntityEmergingGrowthCompany_7d4078fb-cfef-46bb-a477-76904a3853be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8367e341-f46f-478c-95c0-e5d07ba4a1a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_AmendmentFlag_8367e341-f46f-478c-95c0-e5d07ba4a1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_200a9904-4fd0-47d2-84ce-09850a72a353" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2704be6-448c-4814-a1ca-4fb44f928f38" xlink:to="loc_dei_EntityCentralIndexKey_200a9904-4fd0-47d2-84ce-09850a72a353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_03a.jpg
<TEXT>
begin 644 image_03a.jpg
MB5!.1PT*&@H    -24A$4@   O\   &1" 8   #R[=R5    "7!(67,  $SE
M  !,Y0%USO"5  ![9$E$051XVNS6,0$   S",/R;!@D3L$1"KZ8  , +D0
M ,P_  !@_@$  /,/  "8?P  P/P#  #F'P  ,/\  (#Y!P  S#\  )A_  #
M_ ,  .8?   P_P  @/D'  #,/P  8/X!  #S#P  F'\  ,#\ P" ^0<  ,P_
M  !@_@$  /,/  "8?P  P/P#  #F'P  ,/\  (#Y!P  \P\  )A_  # _ ,
M .8?   P_P  @/D'  #,/P  8/X!  #S#P  F'\  ##_  " ^0<  ,P_ ,!M
M    ___LW0E0E&>>Q_'&S!@UD9C5>.28VDR2F8F3W>S4.)ND=ITK8W82,Y6X
M-<EDQC.:Q)R.1]08XR9$C9K13$PFB2)@N&*K(*""R-'<-PA*R]5@0P,-W0UT
MTS1-7_#;I[LY&@5LE%G)SN]3]2^M4NBNE[;J^[P^[_L"1'2#2'@(B(B(B(@8
M_T1$1$1$Q/@G(B(B(B+&/Q$1$1$1,?Z)B(B(B(CQ3T1$1$1$C'\B(B(B(F+\
M$Q$1$1$1XY^(B(B(B!C_1$1$1$2,?R(B(B(B8OP3$1$1$1'CGXB(B(B(&/]$
M1$1$1,3X)R(B(B(BQC\1$1'153EZ )/5 4.7 UWV;O3T]/"@$#'^B8B(Z/^C
M3IL#=08+Y)I.:$PV=#/^B1C_1$1$].UE[^Y!F]D.5;O5-<[8[YN+6C,2JO4X
M6JI#9ET[E/HNU.DMKFDR6M%N<<!B[X:#BP(BQC\1$1&-?ZTB_*,K6K$QJ0X;
M$FNQ[JRR?UX_78.ED95X[F@Y5D95XL^QU5@75X-UXM=]&2HD5+6BIL4,O?@>
M1,3X)R(BHG'NDMXBHK\.DW?GX;L[<S!A>PY\/LR&CU\6?#X0\WXF?/XG0TPZ
M?+:EP><],5M3,>^+0NR4U2)#J8=*W\4#2<3X)R(BHO&JWFC%284>V](:\,O0
M,GQG9RXF[!#A+^)?XI<-B0A_UXCXEXCXEVQ+AT2$OV2KF'=3<<^>'#QU^#S6
MGU;@TPP5HN0:R)M-KFU UZNLL1W2'!6^2%"XYZP"?SM;-3#QE0C+4"*^1(UB
M91NT[5Q\$..?B(B(:%C9#1UX*5:)NSXOAN_>0OCLR'6-Y$/OXG^B^/TTOPS<
MNR<;\[\JQ#)I*:0E36CONOXM0)'Y]7AF7R9^O"D>/]YX!G/?/H,'G;,A3DPL
M'EP?B]]^E(*U7Q<A**4&\GH#?Z#$^"<B(J)O%V6'#4EJ,T[4FCRF ]%B2MNL
M,-M[,%;7ULIJV_%,A *2C_(AV9D'B3/\MWL?_Y(M*9"\DX*;MZ;@SAT9F+<_
M%_LSZEP7#U\+J[T;%6HCXL0"8D-X">9NC(?ORA.8NC(24U^,Q*TK(G"+<Y8?
MQRW+CN&^-2?Q:[\DK/;/PZ>QY4@XKX:BR<@[$A'CGXB(B+X=3M>;L3Q#BY^?
M4>/G<8WNB6W XW$-^++, (T(:V?<CL7]]L<J_B>\(\-DL0"8LST=VY.4T)FL
MU_1^C&8;0C+KL&A_#GZR-1&S7S]Y9?P[P[\W_J>OBL#W7H_&W'6G\-C6L_C#
M)QDXFE4+FZ.;'R1B_!,1$='XTFGO@=)D1V&+M7<L>.]<&^Z+5$%RN,8]0=60
M!"KPW2 %EJ8V([;.A'QM%PK$5!BL:+.,/G1;Q *BK*4+!\YI\8NP\NN.?\EF
M&22;DC'Y71G6G:Q"A;831HO==0M1KXZ#U8':EDZD5NCP9D@)[GCC%*:^% 7?
M52>&CG\1_JY9>A13ED@Q9;$4DQ<?P3VOGL"&X"+D5>F@THW-M0=$C'\B(B(:
M$[4B_ ]4=6!I5@N69CI'AT=C&S'MF]HKXG^"F+D1M?CO!#66R)JP)%D-O\(6
MY&I&?Z%K>GT'MJ8W8H&T$O=\<7[,XO_F+<E8<D2.:+D6Y1J3:P'@C;I6,P+2
M:['$OP"/?)B"VU^-&2+^(T:._S\=P3^M.(;'WHW'BL^S$)I6 XV!%P$3XY^(
MB(AN,&MW#PS6;LB:NO!\N@Z2T#HQ(OA#E) $B_GZTA7Q[YH ,?Y5D!RLA.1
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M>^:_6_CW%?])7>(_X=N+?_7$M>CVH%WY_B:[&WJK"]7J"#V-A%;E:QQN#_^
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MF3+?H]GO/JG=8[;VV7A'4<1Y'/AW(2=B=?LS^'BTW,K*,]DW25?2F\TWK;7
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MD= +JH?2TI.+*6 0Q D[R2F9JG4"AHHA*IJV]MWC#!,G6G&2KJ:K9XY5%0R
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MO'M%LL8C0 E<K"9!$.F]7IR_K>?T"VO$0\.Y^"O6_ZPVN)IR7^_TFZ4J498
MO=QXIC$)J3)U_F:'B$M4Z'#2$/8F( & V+"V^&^@M>)__M)M:F40]V&/7\*'
M1!.K@*;&+(["1'$&21O>;W.N5E75?[E<=%R*VO3J"#'[/R^-DB4K?Y0;&3EJ
M;D#,VEK\-X#X0QSBD Z\6W_4>3H?8@2)'MXCW.-OG79D+DYH/AC:BM5T'%B
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M4XMX^LS%N%Q#L0C_S&R8GIHIK;NF2*'/W4]\1O4'.;G^PV9H!-2K,?2-.FS
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M\S-B(_2J8#.0 =ZI HWT.\2?[]ZM_Q1M/$;Y P?$R+]_-LLYSU LGIU(;%A
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M_7Y?.RU.TI@L6P@F/3P>R?NJ[<WKZODYR4D3 (!;R.=,    XA\  !#_  "
M^ < @/]3,5OFZI6)U"Z/?'Q7,CXRD=F9PCCB'P" 1G)E<"RG#I_-SE\?^O@.
MY]T#9S(R,&H<\0\ 0".Y]-% 7OK9JWGT"QOJUY1';VO*UJ=WYV+;9>.(?P
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MD?KKH+(1(/X!  #Q#P  B'\  $#\ P  XA\  !#_  " ^ <  ,0_  "(?P
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MK^D<1.E.B)-+(-)?AG/XZ=[GV/,0V:]!%*^"K,H ;)W;CX@8_T1$1*.%-)J
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M#P  XA\  !#_  " ^ <  ,0_   @_@$  /$/  "(?P  0/P#  #B'P  $/\
M "#^ 0  \0\  (A_  ! _ ,  .(?   0_P  @/@'  #$/P  (/X! $#\ P
MXA\  !#_  " ^ <  ,0_   @_@$  /$/  "(?P  0/P#  #B'P  Q#\  "#^
M ?[8#0  ___MUC$!   ,PK#Y-\U4P)5(Z-4$ )@Z"0  P/P#  #F'P  ,/\
M (#Y!P  S#\  &#^ 0  \P\  )A_  # _ , @/D'  #,/P  8/X!  #S#P
?F'\  ,#\ P  !0\*/I.2WM?IR     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46667444124496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Nov. 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 12,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NOVAVAX, INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-26770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-2816046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">700 Quince Orchard Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Gaithersburg<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(240)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">268-2000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NVAX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001000694<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MHM9]+_3>;SR*Y<JZ&_Z@E[$EGW'[9S;5T/)+E5BD7!JA)-%\T?>&X=4U;;F
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M"_!\H91];[A3:_FCP^ _4$L#!!0    ( )= ;%F?H!OPL0(  .(,   -
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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MBBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @
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MX3]>?P%02P$"% ,4    " "70&Q9!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( )= ;%F*MNTK[@
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( )= ;%F97)PC$ 8  )PG   3              "  <P!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ET!L61;]81E'!   @!   !@
M             ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( )= ;%F?H!OPL0(  .(,   -              "  8H,  !X;"]S
M='EL97,N>&UL4$L! A0#%     @ ET!L69>*NQS     $P(   L
M     ( !9@\  %]R96QS+RYR96QS4$L! A0#%     @ ET!L61E%%?4W 0
M)P(   \              ( !3Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( )= ;%DD'INBK0   /@!   :              "  ;,1  !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( )= ;%EED'F2&0$  ,\#
M   3              "  9@2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   )  D /@(  .(3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nvax-20241112.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="nvax-20241112.htm">nvax-20241112.htm</File>
    <File>nvax-20241112.xsd</File>
    <File>nvax-20241112_lab.xml</File>
    <File>nvax-20241112_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nvax-20241112.htm": {
   "nsprefix": "nvax",
   "nsuri": "http://www.novavax.com/20241112",
   "dts": {
    "inline": {
     "local": [
      "nvax-20241112.htm"
     ]
    },
    "schema": {
     "local": [
      "nvax-20241112.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "nvax-20241112_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nvax-20241112_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.novavax.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20241112.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20241112.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001000694-24-000040-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001000694-24-000040-xbrl.zip
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M@\7X>&PR8/% P/_( OXR+ ">(2YP.*='.*<+@)"WX!!N93Q@+VS6RT_,Y6I
M!!<)5X"Z#,+K0%./<5:?"=YP7#R)!V$D_VO88Q0.6<9J\6 NDB@<"1X@BQQ*
MI5(FFHP\LH7P9"OPHXF?#A.?9^PU8Y<2CQK.47H)]T'^7L-KMD.C ^L6T>'
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M]D:ED&<7-^CM,3P\52MTG,M+X#1,5C>P@XOO(Q&H!;F$!_&^*0<P(;.+Z33
M?!,W3B**WR++):>]!;3D^@EQ=1[H$/%W.415T6G]#<@"CCI.TT>)" I);8@,
M"_;KV/C?VL.05\*'#Z\M]I9BS3XMHZBXWXC'/H1GK]G1U5N""M@+PI##XB1I
M4ILBS>#P*<6'P.%@=K!'3/RGOD @[39)35\XV6Z2(L_"%QY="V)W>;K@7(I(
M$2'' SCR F'Y8PR*Y%$1/.R)#,2FUGLFWZ@W%[S1JC)VRO!6CF'7@%!*Y L
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M]N MW1K-[!).#K6(K;&4<HW,=DHPG+,@736:'7;=7D80_%!%M0,6/JQ]P-7
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MP+E8$V/S2]$&MMLHBF(/$:TE*WH-UV8L5U"1OM%SK^=_>M*PB@$U,V_ 3O4
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M\$ >(!\02]*4?7,Z;U_64=I@' <Y+%IPN&F[_Q?;Z R[%5],G@%02P,$%
M  @ ET!L61TN2W']"0  ?50  !4   !N=F%X+3(P,C0Q,3$R7VQA8BYX;6S-
MG%UOV\@5AN_S*Z;N30OLB3CD\"M(O$B]21'4FQBQ@UVT*(3YM(E(I$'1L?WO
M.Z0DF[)(:68H,;VQ96ETWO..Y^'A&5)Z^^O#?(9^R'*1%?F[$_S:.T$RYX7(
M\NMW)]^N/D)R\NOIJU=O_P+PYS^^GJ/?"GXWEWF%SDI)*RG0?5;=H.I&HC^*
M\GOV@Z*+&:U44<X!3INWG16WCV5V?5,AW_/)>MCZU?)-0H00"8XA3&0*1$H?
M$L5\(,3W0U]XC%/UR_4;_686"D& J3#6PT0*J?(DT(2$21BFT@M($W26Y=_?
MU#\874BD[>6+YL]W)S=5=?MF,KF_OW_]P,K9ZZ*\GOB>%TS6HT]6PQ^VQM\'
MS6B<INFD>?5IZ"+K&JC#XLF?OY]?\ALYIY#EBXKFO!989&\6S9/G!:=5,^M[
M\T*](^J_8#T,ZJ< ^Q#@UP\+<7+Z"J'E=)3%3'Z5"M6_OWW]U"N93NH1DUQ>
MU__;"UEFA;BL:%F=4R9G.OLF6O5X*]^=+++Y[4RNG[LII>H..RO+C:AUEFF=
M)8[J+/_:)S89D/Z!\JVV<SU <HW=SX?*<=><?CY8NE?Z""&/GW!+9G#*RP7U
M(1=CK=TGJ<&I'S_C0RV+HJ*S$9;%LTPKY5G]Q+E^M)*I ^TXF#8ZJT-W*U7Y
M4,E<R.71<B,TRL2[$_UH*F0VO93\KLRJQP\/_(;FU_(SG<LIB]) >'X*L2\B
M()AXP'P:@?"D"F*I5,#DM'I:TU.9P[?+M7RCL5O@Q,)9U4-H*1?%7<F7M4V+
MUG5]F<?I6A*M-5$M^G;RG)[#G,R.[G1V3),%WP@\JXMT4;YT4O"]3IX7_4);
M:6PL)']]7?R8Z+=J.WY0/X#Z0;/6>P-.MOX+[\MUEK3D>Z9L-6+""WW^<5O!
MQNRILIB;V:D*LW_@<MJTZ DJ2B%+?4[98:!S&6&?76753$X#SD0B@T0?"'P!
MA"H%5)\) @XB262,]0]LB]4Z^)&1:C10H1#V_\;^CM;J]DP]388Y3RX6[5BR
M=><$TTL;@T!Z"C8Z1"]M= &T-<8>GC]T'%W SHKY_"[/EAW%8AJG41)[H0 >
M^1A(%/A I>>#8#BB:13'1/BF!'4J'!FCE2;:%#6GJ'M6]J,TV*L=3Y8VK7#:
M:<6)J>Z(HX&UTU";KMT#[1&K&_79Q4V1R\]W<R;+*>->$%&IH*Y20 +"(/5\
M IAZ@J0XIAYGIG2]#'YDL!HYU.BAI: Y5%OSL)^G(>[L4+(P9H51GP,G@K:"
MC09/GXTV-[UC[)&Y*FF]@WCY.&?%;!I2#\=12$ $7@PDI H27U$0(0YI1&C$
M16S*RT;D8Y_,+;704LP<E$WW^REQ]F1Y]F9FQPJ/SM2=V-B,-!H8G0;:5'0/
ML$?B0U[I,[Y/.2_*VZ)LBM)E12MY5MSE5?EX5@@Y#544"AD)"$7,=&'!$;
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M!500+B5G-.4\5; '0%XQW0N.;.QP#-5T3&!<X->/\:9^J'*'8YY44A$+2+0
M:XDR%",2()7U >3 O<@;AGM!H;X3*';4<TQ(=.NBC_$ZUO=%Y2#'"9 RRATN
MBRRBG06*VVTO< C,0F*=3U,;]L?%-]9[P:&_$SB&*#LF0J[K56/*/XO;;MDL
M(,.A+GA"TTRA-"XCBBI!LM0XE6(44MO]\;%ENU\QBWXG>.PNZX'A: >]\PBF
M\ULSE1IE'$FM$RB HT3+5!&DV^/1ZF1@&>-K:_T &'$Y<V?I#ISR]K%'>;VH
MJ\WV26J%(QE(8KWT*(#)"*Z$)*&*4YD$EN@@!Z7]6XO]4C_B*N8@"0^<_M]C
MT3107=3+Y5WUO$5:Y8)GRH,5!+2Q1*0\Q?DL,R2Q4GC+J,7A;! #KYKM!\*(
M:YC#Q3PP#9_KLG!%4U3S7W"!$PM3YBQCPN T15+#</8RR+)F@B+0,F-24,Y2
M,0B%ES;[<3#B&N5 &0\,P76$EF# A6WW?*Y]M!L_!O0C#XPY=-20ML:&461
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M2P$"% ,4    " "70&Q9JV,_R6,"   #!P  $0              @ &U-@
M;G9A>"TR,#(T,3$Q,BYX<V102P$"% ,4    " "70&Q9'2Y+<?T)  !]5
M%0              @ %'.0  ;G9A>"TR,#(T,3$Q,E]L86(N>&UL4$L! A0#
M%     @ ET!L65"#R#2L!@  Z#   !4              ( !=T,  &YV87@M
F,C R-#$Q,3)?<')E+GAM;%!+!08     !0 % % !  !62@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>nvax-20241112_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nvax-20241112.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001000694</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-11-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">NOVAVAX, INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">0-26770</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">22-2816046</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">700 Quince Orchard Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Gaithersburg</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">20878</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">(240)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">268-2000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, Par Value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">NVAX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
